|
|
|
市場調査レポート
体外診断（IVD）市場：2009〜2024年
In Vitro Diagnostics Market Analysis 2009-2024
| 発行 |
Visiongain |
| 出版日 |
2009年05月 |
商品コード |
92483 |
| ページ情報 |
英文 130 |
| 価格 |
|
|
Abstract
New innovative report discusses how the global IVD market will develop in
light of commercial opportunities and high technological.potential.
In vitro diagnostics constitute an important, growing healthcare industry and
market, one that is increasingly biotechnological and closely aligned with
pharma. In vitro diagnostic (IVD) tests provide essential information about
physiological states, aiding diagnoses and choice of treatments. IVD' s
usefulness in drug development - especially via biomarkers - constitutes a
major advance, and an expanding market opportunity. Our new report - In Vitro
Diagnostics: Market Analysis 2009-2024 - analyses the global IVD market
comprehensively. This new study provides sales forecasts and discussions of
emerging technologies and commercial opportunities, along with other
information that you require.
From 2009 onwards, visiongain believes that worldwide investment in IVD
testing will increase, due to a variety of factors including: Greater
awareness of tests' availability and usefulness More-widely applicable,
accurate and usable tests emerging Increasing appreciation of early diagnosis,
both for patient quality of life and cost efficiencies Progressive harnessing
of biotechnologies, especially in more-personalised medicine, including
theranostics, as well as medical research.
The global IVD market generated sales of over $40bn in 2008. Visiongain
predicts that the market will generate nearly $60bn in 2014. What will it be
worth in 2019 and in 2024? Which tests will be most commercially successful?
How will sales for genetic screening perform in coming years? In Vitro
Diagnostics: Market Analysis 2009-2024 answers these and other crucial
questions.
Highlights of In Vitro Diagnostics: Market Analysis 2009-2024
Highlights of this report include:
- Market sizes and sales growth of major IVD test types from 2009 to 2024
- Individual market forecasts and discussion of the following diagnostic
areas:
- Cholesterol
- HIV
- Pregnancy/fertility
- Diabetes/glucose
- Genetics
- Influenza
- Cancer/oncology
- Drugs of abuse
- Regional market analyses for IVD tests
- Analyses of commercial drivers and restraints, including SWOT analysis
- Discussion of the value of over-the-counter/at-home products
- Discussion of diagnostic test companies.
Comprehensive analysis of the IVD market area
In Vitro Diagnostics: Market Analysis 2009-2024 examines that sector
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts,
discussions of pipeline developments and analysis of commercial drivers and
restraints. There are detailed tables and figures included, as well as expert
opinion from an original survey. The result is a comprehensive market- and
industry-centred report, with detailed analyses and informed opinion to
benefit your work.
Why you should buy In Vitro Diagnostics: Market Analysis 2009-2024
Benefits from purchasing this report include your receiving:
- Detailed sales forecasts for specific IVD markets, with market shares and
growth data
- Discussions why certain IVD test markets will grow more quickly than
others, with future and pipeline developments covered
- A review of leading IVD companies, and recent alliances/mergers
- Insights into regional differences in IVD adoption
- Analyses of which markets are most saturated
- Analyses of which markets have the most scope and potential for expansion
- A discussion of unmet medical needs and how these will affect certain
markets, as well as assessment of commercial drivers and restraints.
Table of Contents
1 Executive Summary
- 1.1 Focus of this Report
- 1.1.1 This Report Discusses IVD Tests According to Applications
- 1.1.2 How Companies are Discussed
- 1.1.3 Forecasts Include Laboratory-Only Companies
- 1.2 Crucial Points
- 1.2.1 Worldwide IVD Market Will Grow Well for the Next 15 Years
- 1.2.2 Short-Term Growth Led by Pregnancy, Influenza and Oncology Tests
- 1.2.3 SWOT Analysis
- 1.3 Aim, Scope and Format of this Report
- 1.4 Research Methods
2 In Vitro Diagnostics (IVD) and Point of Care
- 2.1 What Are IVD Tests?
- 2.2 How IVDs are Regulated by the FDA
- 2.3 Types of IVD Tests
- 2.4 Diagnostics Historically Separate from Pharmacological Treatment
- 2.5 Relative Costs of IVDs
- 2.6 Point of Care Tests (POCTs)
- 2.6.1 POCTs and Hospital Stays
- 2.6.2 What Home POCTs Say About the IVD Market
- 2.7 Laboratory IVD Tests versus Point of Care Testing
- 2.7.1 Diagnosis Turnover Rates
- 2.7.2 How Quickly Are Results Needed?
- 2.7.3 How Much do Shorter Turnaround Times Improve Treatment?
- 2.7.4 Economies of Scale
3 IVD Market Summary
- 3.1 Whole Market Analysis
- 3.2 Market Summary of Five IVD Tests with 2008 Sales of Over $5bn
- 3.3 Market Summary of Four IVD Tests with 2008 Sales Under $5bn
4 Genetic Tests
- 4.1 Genetic Tests: Medicine of the Future?
- 4.1.1 Genetic Tests and Tailored Medicine
- 4.2 Market Forecast, 2009-2024
- 4.3 2009 Call for Genetic Test Standards
- 4.4 Genetics and Oncology
- 4.4.1 BRCA1 and BRCA2 Genetic Tests
- 4.4.2 Genetics and HER2: Success Story
- 4.4.3 HER2 and Cancer: How IVDs and Therapy Interconnect
- 4.4.4 Genetics and Response to Gleevec for Gastrointestinal Cancer
- 4.5 Genetics and Statins
- 4.5.1 Celera' s Genetic Test for Statin Responsiveness: the KIF6 Allele
- 4.5.2 Interview with Thomas White, PhD, Chief Scientific Officer and VP
of Research, Celera
- 4.6 Genetic Test Companies
- 4.6.1 Myriad Genetics
- 4.6.2 deCODE Genetics
- 4.6.3 23andMe
- 4.6.4 Navigenics
- 4.7 Market by Region: Forecast Discussion
- 4.7.1 US
- 4.7.2 Japan and China
- 4.7.3 Europe
5 Oncology Tests
- 5.1 How Cancer is Diagnosed: Currently and in the Future
- 5.2 Market Forecast: 2009-2024
- 5.3 Lung Cancer
- 5.3.1 Almac Diagnostics
- 5.3.2 Lung Cancer IVD: Worldwide Unmet Need
- 5.4 Prostate Cancer
- 5.4.1 Gen-Probe Incorporated
- 5.4.2 Gen-Probe and DiagnoCure Incorporated
- 5.4.3 Timeline for a PCA3 Point of Care Test
- 5.5 Colorectal Cancer
- 5.5.1 Quest Diagnostics
- 5.5.2 DiagnoCure Inc.: Molecular Diagnostics for Cancer
- 5.5.3 Aventir Biotech LLC: First FDA-Approved Faecal Occult Blood Test
- 5.5.4 Alpha Laboratories
- 5.6 Human Papillomavirus (HPV) and Cervical Cancer
- 5.6.1 Digene/Qiagen
- 5.6.2 Cytyc and Hologic
6 Diabetes/Glucose Tests and Monitoring
- 6.1 Brief Overview of Diabetes
- 6.2 Market Forecast, 2009-2024
- 6.3 Glucose IVD Market by Subdivision: Diagnostic Tests and Monitoring
Devices
- 6.4 Types of Tests
- 6.4.1 Blood Tests
- 6.4.2 Urine Tests
- 6.5 Diabetes IVD Assessment Targets
- 6.5.1 Ketones
- 6.5.2 Microalbuminurea
- 6.5.3 Glucose
- 6.6 Top Diabetes IVD Companies
- 6.6.1 Lifescan/Johnson & Johnson
- 6.6.2 Roche
- 6.6.3 Abbott
- 6.6.4 Bayer Diagnostics
- 6.6.5 Home Diagnostics, Inc.
- 6.7 Immediate Results: Crucial for Glucose Monitoring and Point of Care
Testing
- 6.8 Future Opportunities in the Diabetes/Glucose IVD Market
- 6.9 Market by Region: Forecast Discussion
- 6.9.1 India and China
- 6.9.2 United States
- 6.9.3 Europe
7 Cholesterol Tests
- 7.1 Market Forecast, 2009-2024
- 7.2 Cholesterol Testing Companies
- 7.2.1 Polymer Technology Systems (PTS)
- 7.2.2 Roche Diagnostics
- 7.2.3 Home Access Health Corporation
- 7.2.4 Atherotech, Inc.
- 7.3 Market by Region: Forecast Discussion
- 7.3.1 Europe
- 7.3.2 US
- 7.3.3 India
- 7.3.4 South America
8 HIV Tests
- 8.1 Market Forecast, 2009-2024
- 8.2 OTC HIV Tests: The Debate
- 8.2.1 Home Testing vs. Home Sampling
- 8.2.2 Home Tests and Home Results Not Approved
- 8.3 HIV Testing Companies
- 8.3.1 Home Access Health Corporation
- 8.3.2 OraSure Technologies
- 8.3.3 MedMira
- 8.3.4 Novartis/Chiron
- 8.4 Market by Region: Forecast Discussion
- 8.4.1 Europe
- 8.4.2 US
- 8.4.3 Asia
- 8.4.4 Africa: Where the HIV Problem is Worst
9 Influenza Tests
- 9.1 Market Forecast, 2009-2024
- 9.2 Test Targets
- 9.3 Typing: A and B Strains
- 9.3.1 Rapid Tests: 15 Minutes or Less
- 9.4 Rapid Test Companies
- 9.4.1 Becton, Dickinson and Company
- 9.4.2 Inverness Medical Innovations, Inc.
- 9.4.3 Quidel
- 9.4.4 SA Scientific, Ltd.
- 9.4.5 Meridian Bioscience, Inc.
- 9.5 2009 Swine Flu as Case Study
- 9.6 Avian Flu: H5N1
- 9.6.1 IVD Market Forecast and Avian Flu
- 9.6.2 Avian Flu Tests
- 9.6.3 Arbor Vita Corporation
- 9.7 Market by Region: Forecast Discussion
- 9.7.1 US
- 9.7.2 Japan: The Second-Largest Flu Market
- 9.7.3 Europe
- 9.7.4 Hong Kong: Site of Original Avian Flu Outbreak in Human Beings
- 9.7.5 Sites of Recent Avian Flu Outbreaks
10 Drugs of Abuse Tests
- 10.1 Market Forecast
- 10.2 Types of Tests: Individual and Multiple Assays
- 10.3 OTC Test Companies
- 10.3.1 Inverness Medical Innovations/First Check Diagnostics
- 10.3.2 BTNX Inc.
- 10.3.3 Phamatech
- 10.3.4 Alfa Scientific
- 10.3.5 ACON Laboratories/Inverness Medical Innovations
- 10.4 Market by Region: Forecast Discussion
- 10.4.1 US
- 10.4.2 Europe: The European Workplace Drug Testing Society
11 Fertility, Ovulation and Pregnancy Tests
- 11.1 Market Forecast
- 11.2 Male and Fertility Tests: Relative Sales
- 11.3 Over-the-Counter Tests: The Largest Market?
- 11.3.1 Pregnancy Tests
- 11.3.2 Ovulation Tests: As Contraceptive and Pro-Conception Tools
- 11.3.3 Female Fertility Tests
- 11.3.4 Male Fertility Tests: Improving Products
- 11.4 OTC Test Companies
- 11.4.1 Church & Dwight Co, Inc.
- 11.4.2 Swiss Precision Diagnostics: Inverness Medical Innovations and
Procter & Gamble
- 11.4.3 Johnson & Johnson
- 11.4.4 Genosis PLC/The LifeStyle Company
- 11.5 Market by Region: Forecast Discussion
- 11.5.1 US
- 11.5.2 Europe
- 11.5.3 Japan
- 11.5.4 South America
12 Conclusions
- 12.1 Most IVD Test Markets are Growth Markets
- 12.2 Growth Drivers
- 12.2.1 The Greatest Unmet IVD Need
- 12.3 Growth-Limiting Factors
- 12.3.1 Growth-Limiting Factors for Specific Markets
- 12.3.2 Saturated Markets
- 12.4 Over the Counter Tests: The Added Value of Convenience
- 12.5 Diagnostic Innovation: Improving the Future of Medicine
|
 |
